Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Jul 2011 13:01

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Scancell Holdings plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Calculus Capital Limitednotification obligation:iii 4. Full name of shareholder(s) HSBC Global Custody (UK) Limited (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 26 July 2011reached: v 6. Date on which issuer notified: 26 July 2011 7. Threshold(s) that is/are crossed or 10,11,12,13%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction Number Number Number Number of voting % of voting rightsif possible of of of shares rights x using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii Ordinary Shares ISIN: 15,277,780 15,277,780 25,277,780 25,277,780 13.02 % GB00B39J5N63 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting % of voting financial date xvii Conversion rights instrument rights xix, xx instrument period refers to xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 25,277,780 13.02 %

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease N/Ato hold: 12. Date on which proxy holder will cease to hold N/Avoting rights: 13. Additional information: N/A 14. Contact name: Calculus Capital Limited 15. Contact telephone number: 0207 493 4940

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
12th Oct 20127:00 amRNSFinal Results
8th Oct 201210:43 amRNSHolding(s) in Company
8th Oct 201210:43 amRNSHolding(s) in Company
8th Oct 201210:31 amRNSNotice of Results and Share Price Movement
3rd Oct 20123:30 pmRNSChange of Advisers
10th Sep 201211:10 amRNSHolding(s) in Company
3rd Sep 20125:39 pmRNSHolding(s) in Company
23rd Aug 20127:00 amRNSHolding(s) in Company
20th Aug 20124:03 pmRNSHolding(s) in Company
20th Aug 20124:01 pmRNSMarket Update
17th Aug 20129:24 amRNSHolding(s) in Company
15th Aug 20121:12 pmRNSModitope Vaccine Technology Platform
19th Jun 20127:00 amRNSLong Term Treatment Approval
25th May 20127:00 amRNSVesting of Ichor Options
2nd May 20127:00 amRNSSCIB1 Update
17th Apr 20127:00 amRNSSCIB1 Trial Update
16th Apr 201211:34 amRNSHolding(s) in Company
13th Mar 20128:23 amRNSNotice of Investor Meeting
9th Mar 20127:00 amRNSPatent Approval
29th Feb 20123:49 pmRNSChange of Registered Office
31st Jan 20127:00 amRNSHalf Year Results
13th Dec 20114:28 pmPRNIssue of Equity
17th Nov 201111:29 amPRNHoldings in Company
4th Nov 20117:00 amPRNConfirmation of GBP2.85 million payment
25th Oct 20117:00 amPRNProgress on possible GBP2.85m payment
19th Aug 201112:25 pmPRNHolding(s) in Company
18th Aug 201111:37 amPRNAppointment of Director
17th Aug 20117:00 amPRNSCIB1: Safety Review and Dose Escalation
26th Jul 20111:01 pmPRNHolding(s) in Company
25th Jul 201112:45 pmPRNAGM & EGM Statement
30th Jun 201111:48 amPRNChange of Board Structure
30th Jun 201111:46 amPRNDevelopment of new vaccine for treating lung cancer
30th Jun 201111:44 amPRNPlacing to raise £1.73 million
30th Jun 201111:37 amPRNFinal Results
3rd Jun 20117:00 amPRNAppointment of Broker
31st Jan 20118:30 amPRNInterim Results
31st Jan 20117:00 amPRNSCIB1: Safety Review and Dose Escalation
28th Jan 20117:00 amPRNRe: SCIB1 Clinical Trial Patient Recruitment
13th Jan 20117:00 amPRNIssue of Equity
14th Dec 20102:25 pmPRNResult of AGM
14th Dec 20107:00 amPRNAGM Statement
7th Sep 201011:00 amPRNRe: ImmuneRegen Strategic Collaboration
6th Sep 20107:00 amPRNAppointment of Broker
10th Aug 20107:00 amPRNLicence Agreement with Cancer Research Technology

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.